| Company Name: |
Changzhou Hopschain Chemical Co.,Ltd.
|
| Tel: |
85528066 13775048983 |
| Email: |
sales@hopschem.com |
| Products Intro: |
Product Name:CD532
CAS:1639009-81-6
Purity:95+% Package:100mg;250mg;500mg;1g;2.5g;5g;10g
|
CD532 manufacturers
- CD532
-
- $33.00
-
2026-07-27
- CAS:1639009-81-6
- Purity: 99.99%
- Supply Ability: 10g
|
| Product Name: | CD532 | | Synonyms: | Urea, N-[4-[[4-[(5-cyclopentyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]phenyl]-N'-[3-(trifluoromethyl)phenyl]-;1-[4-({4-[(5-cyclopentyl-1H-pyrazol-3-yl)imino]-1,4-dihydropyrimidin-2-yl}amino)phenyl]-3-[3-(trifluoromethyl)phenyl]urea;cj5;CD532;Aurora A/MYCN Dual Inhibitor, CD532;1-(4-((4-((5-Cyclopentyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea | | CAS: | 1639009-81-6 | | MF: | C26H25F3N8O | | MW: | 522.52 | | EINECS: | | | Product Categories: | | | Mol File: | 1639009-81-6.mol |  |
| | CD532 Chemical Properties |
| density | 1.464±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Ethanol: soluble | | form | A solid | | pka | 13.86±0.70(Predicted) | | color | White to off-white | | InChIKey | GBMIFBVLJSCVJT-UHFFFAOYSA-N | | SMILES | O=C(NC1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(NC3=NC=CC(NC4=NNC(C5CCCC5)=C4)=N3)C=C2 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | CD532 Usage And Synthesis |
| Uses | CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer[1][2]. | | Definition | ChEBI: CD532 is a member of the class of phenylureas that is urea with 4-[[4-[(5-cyclopentylpyrazol-3-yl)amino]pyrimidin-2-yl]amino]phenyl and 3-[3-(trifluoromethyl)phenyl substituents at positions N1 and N3. It has a role as an antineoplastic agent. It is an aminopyrimidine, a secondary amino compound, a member of pyrazoles, a member of cyclopentanes and a member of phenylureas. | | Biological Activity | Cell permeable: yes', 'Primary Target
Aurora A', 'Reversible: yes', 'Secondary Target
MYCN | | in vivo | CD532 (25 mg/kg; i.p. twice weekly for 3 weeks) decreases the tumor volume and increases survival in mice with subcutaneous sonic hedgehog (SHH)-subtype medulloblastoma[1].
CD532 (60 mg/kg; i.p. for 2 days) decreases the level of MYCN protein in MYCN-amplified neuroblastoma xenografts[1].
CD532 (20 mg/kg; i.p.) shows a serum half-life of ~1.5 hours and AUC0-24 of 27 μMh in mice[1]. | Animal Model: | Homozygous nu/nu mice with SHH-subtype MYCN-expressing medulloblastoma[1] | | Dosage: | 25 mg/kg | | Administration: | I.p. twice weekly for 3 weeks | | Result: | Decreased the level of MYCN protein and tumor volume and increases survival. |
| | IC 50 | Aurora A: 45 nM (IC50) | | References | [1] Gustafson WC, et, al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014 Sep 8;26(3):414-427. DOI:10.1016/j.ccr.2014.07.015
[2] Lee JK, et, al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11;29(4):536-547. DOI:10.1016/j.ccell.2016.03.001 |
| | CD532 Preparation Products And Raw materials |
|